Physician profile
Pavan Bang
NPI 1629430798
$671.16
in general payments reported to CMS, 2019-2025
16 companies · $386 in 2025
The $386 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $25.70 · 2021: $65.35 · 2022: $81.52 · 2023: $113 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $498.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $122.95 | 2021-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Biomarin Pharmaceutical INC. | $114.46 | 2025 | Voxzogo 1.2mg |
| Pfizer INC. | $73.60 | 2023-2025 | |
| Sobi, INC | $54.93 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $54.72 | 2025 | |
| Sanofi Pasteur INC. | $50.19 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $33.93 | 2025 | Zoryve |
| Alk-Abello, INC | $28.46 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $26.05 | 2020-2021 | |
| Noven Therapeutics, LLC | $22.80 | 2025 | Xelstrym |
| Celgene Corporation | $19.00 | 2025 | Zeposia |
| Collegium Pharmaceutical, INC. | $18.08 | 2025 | Jornay Pm |
| Cipher Pharmaceuticals US LLC | $16.54 | 2025 | Natroba, Spinosad |
| Tris Pharma INC | $15.80 | 2025 | Dyanavel Xr |
| Kaleo, INC. | $11.42 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $8.23 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Bang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.